Skip to content

Evaluation of the Effectiveness of a Closed-incision Negative-pressure Therapy (Prevena®) on Bilateral Groin Incision

Evaluation of the Effectiveness of a Closed-incision Negative-pressure Therapy (Prevena®) on Bilateral Groin Incision

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04174183
Acronym
PREVISION
Enrollment
84
Registered
2019-11-22
Start date
2019-12-24
Completion date
2022-07-31
Last updated
2020-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bilateral Vascular Groin Surgery

Brief summary

Closed-incision negative-pressure therapy are medical device that are suspected to reduce groin wound complication in vascular surgery. The aim of this study is to compareon on the same patient a Closed-incision negative-pressure therapy (Prevena®, KCI) versus a traditional gauze dressings after a bilateral vascular groin surgery. To do this, each device is applied on one groin incision and the side, left or right, is randomized.

Detailed description

The prevalence of surgical site infections in groin vascular surgery is 3-44%. The factors causing these infections are well identified: disruption of lymphatic vessels, proximity of genital organs, presence of prosthetic material, etc. The risk of developing an infection of the surgical site is also influenced by the patient's comorbidities and by the surgical context. Closed-incision negative-pressure therapy are medical device that are suspected to reduce groin wound complication in vascular surgery. The mechanisms of action for negative-pressure therapy include protecting the wound bed, splinting soft tissue, reducing oedema,increasing perfusion and enhancing development of granulation tissue. Presently, there are no guidelines for the use of this device or not in groin incision and this decision is left to the surgeon's discretion. The main objective is to demonstrate the superiority of closed-incision negative-pressure therapy over the application of a traditional gauze dressings to reduce the rate of major complications (i.e. requiring an extension of hospitalization time) during bilateral vascular groin surgery. To do this, each device is applied on one groin incision and the side, left or right, is randomized. The secondary objectives are: 1. To demonstrate the superiority of closed-incision negative-pressure therapy over the application of a dry dressing in reducing the score of complications (major and minor) during vascular groin surgery. The complication score is the number of complications observed during the consultation conducted on day four after the surgery, among the following: * Major : 1. Presence of pus 2. Bloody and/or lymphatic discharge 3. Disunity 4. Necrosis * Minor : 5\) Bruising 6) Hematoma 7) Wound extension 2. To compare the rate of major complications between closed-incision negative-pressure therapy and dry dressing application in different clinical settings. 3\. To demonstrate the superiority of closed-incision negative-pressure therapy over the application of a dry dressing in reducing the score of complications 2-3 months after surgery.

Interventions

DEVICEClosed-incision Negative-pressure Therapy - Dry dressing

A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Person affiliated to a health insurance system * Person who has received full information on the organization of the research and has signed his or her informed consent * Person presenting a bilateral vascular groin surgery * Major person

Exclusion criteria

* Person with a known allergy to one of the components of the evaluated product (including: acrylic or silver-based adhesives) * Person with a contraindication to the product(s) being evaluated * Non-collaborative or agitated patient * Patients with hemostasis problems * Persons referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code: * Pregnant woman, parturient or breastfeeding mother * Minor person (not emancipated) * Adult person subject to a legal protection measure (guardianship, curatorship, protection of justice) * Adult person unable to consent * Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1.

Design outcomes

Primary

MeasureTime frameDescription
Wound aspect - major complication4 daysLeft and right wound incision are inspected and the presence of major complication are reported. Major complication : Presence of pus Bloody and/or lymphatic discharge Disunity Necrosis

Secondary

MeasureTime frameDescription
Score of complications4-daysLeft and right wound incision are inspected and the presence of major and minor complication are reported. A score of complications is established. \- Major : Presence of pus Bloody and/or lymphatic discharge Disunity Necrosis \- Minor : Bruising Hematoma Wound extension Each complication amount to 1 point on the complication score.
Major complication in different clinical settings4-daysLeft and right wound incision are inspected and the presence of major complication are reported. Major complication : Presence of pus Bloody and/or lymphatic discharge Disunity Necrosis During the analysis, patient are divided into several group depending of the presence or absence of comorbidities.
Wound aspect - major complication (long term)2-3 monthsLeft and right wound incision are inspected and the presence of major complication are reported. Major complication : Presence of pus Bloody and/or lymphatic discharge Disunity Necrosis

Countries

France

Contacts

Primary ContactNicla Settembre, M.D
n.settembre@chru-nancy.fr+33 3 831 543 84

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026